Trending 
The US Supreme Court on Monday issued a temporary stay that maintains nationwide mail-order access to the abortion pill mifepristone, blocking for now a lower court order that would have restricted its delivery.
This extension provides an additional three days of availability while the court considers an emergency appeal regarding the 5th Circuit Court of Appeals’ ruling.
If that lower ruling were to take effect, it would ban the drug’s delivery by mail and require patients to obtain it in person at health clinics.
The legal dispute stems from a lawsuit filed by the state of Louisiana against the Food and Drug Administration.
Manufacturers Danco Laboratories and GenBioPro requested the high court’s intervention to prevent immediate disruptions to distribution while they challenge the appellate court’s restrictions.
Currently, mifepristone is used in the majority of abortions across the United States and has been a standard, FDA-approved treatment for over 20 years.
This reprieve comes amid a shifting legal landscape following the 2022 overturning of Roe v. Wade.
While anti-abortion groups continue to challenge the medication’s safety, the Supreme Court previously rejected a similar bid to restrict the pill in 2024.
For now, the drug remains accessible via mail and telemedicine as the judiciary weighs the broader implications of the case, with a further update expected by Thursday.
